SCHEMBL20179813

SCHEMBL20179813

CCOC(=O)/C(C(C)=O)=C(\C)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KDM4E B2RXH2 3/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CASP3 P42574 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
CES2 O00748 1/20 0.44
ACHE P22303 1/20 0.44
CES1 P23141 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CYP19A1 P11511 2/20 0.42
HTR7 P34969 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18709565 1.00 MAPT (0.50) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL23332555 0.93 MAPT (0.53) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL3403487 0.84 MAPT (0.48) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL3403489 0.84 MAPT (0.48) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL6067672 0.83 ALDH1A1 (0.54) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL6067677 0.83 ALDH1A1 (0.54) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL15295334 0.81 SMN1; SMN2 (0.44) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL1507996 0.81 KMT2A (0.54) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL9265691 0.81 MAPT (0.50) MAPTKMT2AMEN1LMNACYP1A2
SCHEMBL23332383 0.80 GAA (0.47) KMT2AMEN1LMNACYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11166954-B2 Dihydropyrimidine compound and preparation method and use thereof SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2021-11-09 US disclosed
US-20200253971-A1 DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2020-08-13 US disclosed
US-10696669-B2 Dihydropyrimidine compound and preparation method and use thereof SICHUAN KELUN-BIOTECH BIOPHARMACEUTICALS CO., LTD. (CN) 2020-06-30 US disclosed
WO-2018090862-A1 DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11166954-B2 Dihydropyrimidine compound and preparation method and use thereof DPYD, DHPS, HPRT1 MAPT 1628/4885KMT2A 2032/4885MEN1 2497/4885
US-20200253971-A1 DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF DPYD, DHPS, HPRT1 MAPT 1628/4885KMT2A 2032/4885MEN1 2497/4885
US-10696669-B2 Dihydropyrimidine compound and preparation method and use thereof DPYD, TYMP, DHPS MAPT 2398/4885KMT2A 3060/4885MEN1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.